PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts

[1]  Xiaodong Zhang,et al.  Proton and photon radiosensitization effects of niraparib, a PARP‐1/‐2 inhibitor, on human head and neck cancer cells , 2020, Head & neck.

[2]  B. Monk,et al.  Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. , 2019, The New England journal of medicine.

[3]  A. Grosu,et al.  Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries , 2019, Strahlentherapie und Onkologie.

[4]  Sheridan M. Hoy.  Talazoparib: First Global Approval , 2018, Drugs.

[5]  S. Hurvitz,et al.  Advances in the use of PARP inhibitor therapy for breast cancer , 2018, Drugs in context.

[6]  C. Rudin,et al.  Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts , 2018, Clinical Cancer Research.

[7]  L. Heinzerling,et al.  BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma. , 2018, Anticancer research.

[8]  H. Rupasinghe,et al.  Kinase-targeted cancer therapies: progress, challenges and future directions , 2018, Molecular Cancer.

[9]  J. Utikal,et al.  Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients , 2018, British Journal of Cancer.

[10]  T. Harrer,et al.  Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation , 2017, Oncology letters.

[11]  John Moore,et al.  PARP Inhibition Combined With Thoracic Irradiation Exacerbates Esophageal and Skin Toxicity in C57BL6 Mice. , 2017, International journal of radiation oncology, biology, physics.

[12]  L. Scott.  Niraparib: First Global Approval , 2017, Drugs.

[13]  E. Yang,et al.  Poly(ADP-ribose) polymerase activity and inhibition in cancer. , 2017, Seminars in cell & developmental biology.

[14]  Tobias Karlberg,et al.  Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. , 2017, Journal of medicinal chemistry.

[15]  S. Bhutra,et al.  Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers , 2017, Oncotarget.

[16]  P. Jeggo,et al.  How cancer cells hijack DNA double-strand break repair pathways to gain genomic instability. , 2015, The Biochemical journal.

[17]  W. McBride,et al.  Opportunities and challenges of radiotherapy for treating cancer , 2015, Nature Reviews Clinical Oncology.

[18]  T. Ekblad,et al.  HUMAN ARTD1 (PARP1) - CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR TALAZOPARIB , 2015 .

[19]  C. Berking,et al.  Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. , 2015 .

[20]  H. Taubert,et al.  Targeting of EGFR and HER2 with therapeutic antibodies and siRNA , 2015, Strahlentherapie und Onkologie.

[21]  T. Buchholz,et al.  Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells , 2014, Oncotarget.

[22]  A. Ashworth,et al.  BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency , 2013, Clinical Cancer Research.

[23]  V. Schreiber,et al.  The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. , 2012, Biochemical pharmacology.

[24]  A. Enk,et al.  Transgene expression by oncolytic adenoviruses is modulated by E1B19K deletion in a cell type-dependent manner. , 2009, Virology.

[25]  C. Toniatti,et al.  Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. , 2009, Journal of medicinal chemistry.

[26]  G. Grabenbauer,et al.  Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  J. O’Shaughnessy.  Extending survival with chemotherapy in metastatic breast cancer. , 2005, The oncologist.

[28]  C. Rübe,et al.  Radiosensitivity of Tumor Cell Lines after Pretreatment with the EGFR Tyrosine Kinase Inhibitor ZD1839 (Iressa®) , 2005, Strahlentherapie und Onkologie.

[29]  T. Pawlik,et al.  Role of cell cycle in mediating sensitivity to radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[30]  W. Dewey,et al.  Radiation-induced cycle delay in synchronized Chinese hamster cells: comparison between DNA synthesis and division. , 1973, Radiation research.

[31]  R. Fietkau,et al.  Lethal outcome after pelvic salvage radiotherapy in a patient with prostate cancer due to increased radiosensitivity , 2017, Strahlentherapie und Onkologie.

[32]  Jacqueline Kessler,et al.  Targeting of EGFR and HER 2 with therapeutic antibodies and siRNA A comparative study in glioblastoma cells , 2015 .

[33]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..